| PDA0207 | Interferon-a modulates the host glycosylation machinery during treated HIV infection | Poster exhibition | A24 |
| PDB0102 | Time to viral rebound after interruption of modern antiretroviral therapies | Poster exhibition | B40 |
| PDB0103 | Is DTG+3TC effective and safe in clinical practice? Evidence from real world data | Poster exhibition | B30 |
| PDB0104 | Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis | Poster exhibition | B30 |
| PDB0105 | Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) | Poster exhibition | B32 |
| PDB0106 | Optimizing the management of patients with virologic non-suppression | Poster exhibition | B5 |
| PDB0202 | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-naïve (AMBER) and virologically suppressed (EMERALD) patients with neurologic and/or psychiatric comorbidities: Week 96 subgroup analysis | Poster exhibition | B24 |
| PDB0203 | Task-shared, nurse-delivered, cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV clinics in Kayelitsha, South Africa: A randomized controlled trial | Poster exhibition | B16 |
| PDB0204 | High burden of depression among clients initiating same-day antiretroviral therapy at the Anonymous Clinic, Bangkok Thailand | Poster exhibition | B16 |
| PDB0205 | Longitudinal study of neurocognitive disorders and associated structural brain changes in adolescent HIV | Poster exhibition | B56 |